Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
Etien Yovchev is the co-founder and managing partner of The Recursive, a tech media covering trends in Europe's AI economy.
Dr. Najat Khan of Recursion shared insights into the creation of the Microglia Map and what it could mean for future drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback